Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Carcinoma, Hepatocellular 131Liver Neoplasms 42Carcinoma, Renal Cell 36Leukemia, Myeloid, Acute 32Neoplasm Metastasis 26Breast Neoplasms 24Carcinoma, Non-Small-Cell Lung 22Kidney Neoplasms 16Neoplasms 14Prostatic Neoplasms 12Pancreatic Neoplasms 12Recurrence 11Lung Neoplasms 11Colorectal Neoplasms 10Sarcoma 9Melanoma 9Brain Neoplasms 9Myelodysplastic Syndromes 8Glioblastoma 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Leukemia 6Urinary Bladder Neoplasms 5Thyroid Neoplasms 5Rectal Neoplasms 5Multiple Myeloma 5Leukemia, Myelomonocytic, Chronic 5Stomach Neoplasms 4Ovarian Neoplasms 4Liver Diseases 4Gliosarcoma 4

Interventions

gallium Ga 68 dotatate 5Everolimus 5lanreotide 3cabozantinib 3Nivolumab 3pasireotide 2lutetium Lu 177 dotatate 2Temozolomide 2Sunitinib 2Octreotide 2Ga(III)-DOTATOC 2Erlotinib Hydrochloride 2Capecitabine 2zimberelimab 1veliparib 1telotristat ethyl 1recombinant interferon alpha 2b-like protein 1pertuzumab 1nintedanib 1ibrutinib 1ganitumab 1fluorodopa F 18 1carfilzomib 1aflibercept 1Sorafenib 1Somatostatin 1Serotonin 1Ramucirumab 1Radiotherapy 1Radiation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Carcinoid Tumor × Sorafenib × Clear all
NCT00942682 2014-04-29

Sorafenib in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors

Dana-Farber Cancer Institute

Phase 1 Completed
21 enrolled
EndocrineNET

Carcinoid Tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡